Production of IL-16 correlates with CD4+ Th1 inflammation and phosphorylation of axonal cytoskeleton in multiple sclerosis lesions

Journal of Neuroinflammation

Volumn 3, Issue , 2006, Pages

  Skundric, Dusanka S ^a   Cai, Juan ^a   Cruikshank, William W ^b   Gveric, Djordje ^c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD3 ANTIGEN; CD4 ANTIGEN; CHEMOATTRACTANT; INTERLEUKIN 16; MYELIN; NEUROFILAMENT PROTEIN; STAT1 PROTEIN; TRANSCRIPTION FACTOR T BET; TYROSINE;

ACUTE DISEASE; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; AUTOPSY; AXONAL INJURY; BRAIN REGION; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CELL SPECIFICITY; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOSKELETON; DEGENERATIVE DISEASE; DEMYELINATING DISEASE; ENZYME DEGRADATION; FEMALE; GRAY MATTER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATION; LYMPHOCYTIC INFILTRATION; MALE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; NERVE FIBER; PHENOTYPIC VARIATION; PROTEIN PHOSPHORYLATION; SPINAL CORD; T LYMPHOCYTE ACTIVATION; TH1 CELL; WESTERN BLOTTING; WHITE MATTER;

EID: 33745786381     PISSN: 17422094     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-3-13     Document Type: Article

References (35)

1. Bjartmar C, Trapp BD: Axonal degeneration and progressive neurology disability in multiple sclerosis. Neurotax Res 2003, 5:157-64.
2. Lassmann H, Bruck W, Lucchinetti C: Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001, 7:11-21.
3. Hickey WF, Hsu BL, Kimura H: T-lymphocyte entry into the central nervous system. J Neurosci Res 1991, 28:254-60.
4. Steinman L: Immune therapy for autoimmune diseases. Science 2004, 305:212-216.
5. Li H, Newcombe J, Croome NP, Cuzner MI: Characterization and distribution of phagocytic macrophages in multiple sclerosis plaques. Neuropath Appl Neurobiol 1993, 19:214-23.
6. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH: A Novel Transcription Factor, T-bet, Directs THI Lineage Commitment. Cell 2000, 100:655-69.
7. Lovett-Racke AE, Rocchini AE, Choy J, Northrop SC, Hussain RZ, Ratts RB, Sikder D, Racke NK: Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes. Immunity 2004, 21:719-31.
8. Robinson DS, O'Garra A: Further checkpoints in ThI development. Immunity 2002, 16:755-58.
9. Imada K, Leonard WJ: The Jak-STAT pathway. Mol Immunol 2000, 37:1-11.
10. Lee YJ, Benveniste EN: StartI alpha expression is involved in IFN-gamma induction of the class II transactivator and class II MHC genes. J Immunol 1996, 157:1559-68.
11. Trebst C, Ransohoff RM: Investigating chemokines and chemokine receptors in patients with multiple sclerosis. Arch Neurol 2001, 58:1975-80.
12. Cruikshank W, Center DM: Modulation of lymphocyte migration by human lymphokines. II. Purification of lymphotactic factor (LCF). J Immunol 1982, 128:2569-71.
13. Cruikshank W, Kornfeld H, Center DM: Interleukin-16. J Leukocyte Biol 2000, 67:757-66.
14. Wilson KC, Center DM, Cruikshank WW: The Effect of Interleukin-16 and its Precursor on T Lymphocyte Activation and Growth. Growth Factors 2004, 22:97-104.
15. Lynch EA, Heijens CA, Horst NF, Center DM, Cruikshank WW: Cutting edge: IL 16/CD4 preferentially induces Th1 cell migration: requirement of CCR5. J Immunol 2003, 171:4965-68.
16. Cruikshank WW, Center DM, Nisar N, Wu M, Natke B, Theodore AC, Kornfeld H: Molecular and functional analysis of a lymphocyte chemoattractant factor: Association of biologic function with CD4 expression. Proc Natl Acad Sci USA 1994, 91:5109-13.
17. Mathy NL, Scheuer W, Lanzendorfer M, Honold K, Ambrosius D, Norley S, Kurth R: Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunol 2000, 100:63-69.
18. Center DM, Kornfeld H, Cruikshank WW: Interleukin 16 and its function as a CD4 ligand. Immunol 1996, 17:476-81.
19. Skundric DS, Dai R, Zakarian VL, Bessert D, Skoff RP, Cruikshank WW, Kurjakovic Z: Anti-IL- 16 Therapy Reduces CD4+ T-Cell Infiltration and Improves Paralysis and Histopathology of Relapsing EAE. J Neurosci Res 2005, 79:680-93.
20. Skundric DS, Zhou W, Cruikshank WW, Dai R: Increased level of bioactive IL-16 correlate with disease activity during relapsing experimental autoimmune encephalomyelitis (EAE). J Autoimmun 2005, 25:206-14.
21. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-52.
22. Cuzner ML, Gveric D, Strand C, Loughlin AJ, Paemen L, Opdenakker G, Newcombe J: The expression of tissue type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis-comparison of stages in lesion evolution. J Neuropath Exp Neurol 1996, 55: 1194-204.
23. Yoshimoto T, Wang CR, Yoneto T, Matsuzawa A, Cruikshank WW, Nariuchi H: Role of IL-16 in delayed-type hypersensitivity reaction. Blood 2000, 95:2869-74.
24. Laberge S, Ghaffar O, Boguniewicz M, Center DM, Leung DY, Hamid Q: Association of increased CD4+ T-Cell Infiltration with increased IL-16 gene expression in atopic dermatitis. J Allergy Clin Immunol 1998, 102:645-74.
25. Franz JK, Kolb SA, Hummel KM, Lahrtz F, Neidhart M, Aicher WK, Pap T, Gay RE, Fontana & Gay S: Interleukin-16, produced by synovial fibroblasts, mediates chemoattraction for CD4+T lymphocytes in rheumatoid arthritis. Eur J Immunol 1998, 28:2661-71.
26. Lard LR, Roep BO, Verburgh CA, Zwinderman AH, Huizinga TW: Elevated II-16 levels in patients with systemic lupus erythematosus are associated with disease severity but not with genetic susceptibility to lupus. Lupus 2002, 11:181-5.
27. Schluesener HJ, Seid K, Kretzschmar J, Meyermann R. Leukocyte Chemotactic Factor, a Natural Ligand to CD4, is Expressed by Lymphocytes and Microglial Cells of the MS-Plaque. Neurosci Res 1996, 44:606-611.
28. Gveric D, Cuzner ML, Newcombe J: Insulin-like growth factors and binding proteins in multiple sclerosis plaque. Neuropath and App Neurobio 1999, 25:215-25.
29. Gveric D, Herrera BM, Cuzner ML: Receptors and the Fibrinolytic Response in Multiple Sclerosis Lesions. Am J Pathol 2005, 166:1143-51.
30. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, Schmidbauer M, Parisi JE, Lassmann H: Corticol demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005, 128:2705-12.
31. Kurschner C, Yuzaki M: Neuronal Interleukin-16 (NIL-16): A Dual Function PDZ Domain Protein. Neurosci 1999, 19:7770-7780.
32. Nicoll J, Cruikshank WW, Brazer W, Lui Y, Center DM, Kornfeld H: Identification of Domain in IL-16 Critical for Biological Activity. Immunol 1999, 163:1827-1832.
33. Kaser A, Dunzendorfer S, Offner FA, Ryan T, Schwabegger A, Cruikshank WW, Wiedermann CJ, Tilg H: A role for IL-16 in the crosstalk between dendritic cells and T cells. J Immunol 1999, 163:3232-8.
34. Lighvani AA, Frucht DM, Jankovic D, Yamane H, Aliberti J, Hissong BD, Nguyen BV, Gadina M, Sher A, Paul WE, O'Shea JJ: T-bet is rapidly induced by interferon-γ in lymphoid and myeloid cells. PNAS 2001, 98:1537-42.
35. Petzold A: Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss. Neuro Sci 2005, 233:9183-198.